Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

1. RARE and MREO stocks dropped sharply following study update. 2. Phase 3 portion of Orbit study shows acceptable safety but no early termination. 3. Secondary analysis did not meet statistical significance threshold of p<0.01. 4. Analysts believe market's reaction to study results is overly negative. 5. Positive final outcomes anticipated by Q4 due to lower significance thresholds.